about
G-Quadruplex Forming Oligonucleotides as Anti-HIV AgentsSmart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapyProgress toward in vivo use of siRNAs-IINucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.DNA aptamer evolved by cell-SELEX for recognition of prostate cancer.Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease TherapyLiposomal nanostructures for photosensitizer delivery.A general RNA motif for cellular transfection.Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cellsOptimizing siRNA delivery to the genital mucosaCharacterization of DNA aptamers generated against the soft-shelled turtle iridovirus with antiviral effects.UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CAn RNA alternative to human transferrin: a new tool for targeting human cells.Aptamer-mediated delivery of chemotherapy to pancreatic cancer cellsCurrent progress of RNA aptamer-based therapeutics.Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridgeTherapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.How nanotechnology can enhance docetaxel therapy.Aptamer-based therapeutics: new approaches to combat human viral diseasesNADPH oxidase in brain injury and neurodegenerative disordersSite-specific antibody-polymer conjugates for siRNA delivery.Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies.Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease.Conceptual approaches for lncRNA drug discovery and future strategies.Escort aptamers: new tools for the targeted delivery of therapeutics into cells.Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.Current progress on aptamer-targeted oligonucleotide therapeutics.Advances in targeted delivery of small interfering RNA using simple bioconjugates.Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures.Identification of an aptamer binding to human osteogenic-induced progenitor cells.d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers.Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX.Biomedical Applications of DNA-Conjugated Gold Nanoparticles.Antimicrobial aptamers for detection and inhibition of microbial pathogen growth.In Vitro Selection of Cell-Internalizing DNA Aptamers in a Model System of Inflammatory Kidney Disease.Label-free aptamer-based partial filling technique for enantioseparation and determination of DL-tryptophan with micellar electrokinetic chromatography.
P2860
Q26781549-23B6433E-4F35-4049-8178-B55BF67D6984Q27025832-08788763-309D-4619-AC80-728873F0ADEBQ28255877-9ADFFD52-86C9-4C2A-8C2A-BE92083EFF2EQ30434521-4C7BE7EE-E392-43DE-A385-66EEB570BA73Q33724277-1FB45578-22A6-43BB-9EA3-0A02D67C3E57Q33793416-09AD211E-C6A9-4BF2-A93D-CA60F4DCE348Q33834772-F2A87796-B09D-4C0B-A715-B774EA64F299Q34068206-02E8AB8C-449A-4611-A3F7-A5CA79D34427Q34123063-4D9584D5-C466-4BAE-90E8-E59C00B23DDDQ34232003-CA9C5BEF-6129-4A9E-92E8-7A3E72565F93Q35205365-9AE571DB-6E55-4F84-A49D-7554153424ECQ35335653-09D81D0B-9A29-4A4A-AFF2-8532665E13B1Q35766249-02A13605-AE8F-48F5-B214-28EE51DC8290Q35792236-E4B4ED49-EBC6-4113-A9E7-AB0238C003B0Q35943810-9B2AD5D8-2947-4A70-B44C-DEBA9A8316D9Q36077849-C8CAEFCF-E52B-41A9-AAF7-06D647D57BF8Q36298003-391DC86D-D6EE-4B5C-AE97-451172CBB6C6Q36365202-87BE7783-A9E2-4A70-95D3-80AF730A9BD6Q36512567-B84BC27C-9115-431B-9069-532ECE6254E6Q36839458-AD226637-6530-443B-8DA4-9471EDAEB99CQ37091683-784ADAC3-017B-4BA1-AD98-02A3C17CC17FQ37415958-B2F48981-5322-4741-A7E2-C010180C38FCQ37589114-83C5D95E-2D03-4ADD-8DD6-B13A64750992Q37638814-BAF5D169-DF46-4B27-986E-A0C373181064Q37656119-AC8E2918-A19D-45C8-9608-07F288461FC9Q37910273-8B984BD9-84A9-412A-8582-D6962B83662EQ37978891-B0685A7D-1B57-42A0-9D5F-E4EEDBFFDA0AQ38007555-366587C5-31D2-462B-AB49-3674966D028DQ38014851-6DABA061-87D0-40C6-B8CB-8ADC24BE47E1Q38073792-06549897-B87A-4F84-B832-EC8DDE37A472Q38168595-5FD3E93D-AC8A-43A4-B0E3-197CB185FEAAQ38199518-C03EF3A9-87BF-4205-9538-7C3E0C982255Q38205561-C6541B3A-EF14-403E-B972-6D1AA3C0AC09Q38318816-85515B46-6295-4B8A-8E50-0DDA3EF1516FQ38319321-A335EE23-2D97-4034-8138-939C3006F0C8Q38609277-D3AF5D01-4D81-4A0B-B68C-7C84BD7E58DBQ38728691-4125E919-E121-4048-83DA-EFB9FB1F3964Q39456622-A1974A5C-9781-434B-8CA6-DB283A04311AQ41716145-4CF8585E-DE67-4BDE-804E-D3767F28A923Q45807157-F5CF2DDF-6AAF-4FEB-A7B8-20399B857A4C
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cell-specific aptamer-mediated targeted drug delivery
@ast
Cell-specific aptamer-mediated targeted drug delivery
@en
Cell-specific aptamer-mediated targeted drug delivery
@nl
type
label
Cell-specific aptamer-mediated targeted drug delivery
@ast
Cell-specific aptamer-mediated targeted drug delivery
@en
Cell-specific aptamer-mediated targeted drug delivery
@nl
prefLabel
Cell-specific aptamer-mediated targeted drug delivery
@ast
Cell-specific aptamer-mediated targeted drug delivery
@en
Cell-specific aptamer-mediated targeted drug delivery
@nl
P2860
P356
P1433
P1476
Cell-specific aptamer-mediated targeted drug delivery
@en
P2093
Jiehua Zhou
John J Rossi
P2860
P356
10.1089/OLI.2010.0264
P577
2010-12-23T00:00:00Z